{"filings":[{"id":2550436,"accession_number":"0001193125-26-374788","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-08-28T21:25:56+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Spero enters $100M ATM facility with Jefferies, terminates Cantor ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale Agreement with Jefferies LLC enables up to $100M of common stock in at-the-market offerings once S-3 is effective.","Registration statement on Form S-3 for up to $300M in securities filed Aug 28, 2026; not yet effective, no sales permitted until then.","Jefferies to receive up to 3.0% of gross proceeds for shares sold under the agreement.","Terminated Cantor Fitzgerald ATM agreement effective Aug 28, 2026; no shares sold under it in FY2024 or FY2025, no penalties incurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2216877,"accession_number":"0001193125-26-346855","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-08-12T20:09:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q2 net loss widens to $9.6M; FDA approves Utebzi, $105M financing extends runway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($0.16 diluted EPS) vs $1.7M loss ($0.03) in Q2 2025.","No revenue in Q2 2026 vs $14.2M in Q2 2025; all deferred revenue previously recognized.","Cash $50.8M at June 30, 2026; plus $105M royalty financing extends runway into H2 2029.","FDA approved Utebzi (tebipenem pivoxil) for cUTIs in June 2026; GSK launch expected by end of 2026.","Exclusive license with Innovent for SP001 (anti-CD40L) worldwide ex-Greater China; Phase 2 in IgG4-RD planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":258000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1618837,"accession_number":"0001193125-26-302473","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-07-14T10:30:09+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Spero in-licenses SP001 anti-CD40L antibody from Innovent, secures $105M non-dilutive financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In-licensed SP001 (anti-CD40L) from Innovent; Spero gets ex-China rights. Upfront $35M, milestones up to ~$1.05B, tiered royalties high single to mid-teen %.","SP001 Phase 2-ready; Spero plans Phase 2 in IgG4-RD in Q2 2027. Innovent plans Phase 2 in SjD in China by early 2027.","Secured $105M non-recourse notes from HCRx (KKR) at 10% interest, 9-year maturity, backed by Utebzi milestones/royalties from GSK.","Cash runway extended into H2 2029; proceeds to fund SP001 development.","Spero retains 35% of GSK proceeds after note repayment; HCRx gets 65% after note repayment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1278957,"accession_number":"0001193125-26-283033","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-06-25T21:08:23+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Spero shareholders approve doubling authorized shares to 240M and 2026 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 120M to 240M via certificate of amendment filed June 23, 2026.","2026 Stock Incentive Plan approved; up to 12,895,866 shares may be issued under the plan.","Directors Milind Deshpande, Ph.D. and Kathleen Tregoning reelected as Class III directors until 2029.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 99.5% votes for.","Advisory vote on named executive officer compensation approved with ~96% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1194763,"accession_number":"0001193125-26-277506","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-06-22T20:05:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Spero Therapeutics' Utebzi, first oral carbapenem for cUTIs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Utebzi (tebipenem pivoxil) approved June 17, 2026 for complicated UTIs in adults with limited oral alternatives.","PIVOT-PO trial showed 58.5% overall success vs 60.2% for IV imipenem-cilastatin (adjusted diff -1.3%).","Most common AEs were diarrhea and headache; all mild/moderate and non-serious.","GSK holds exclusive global license (excl. select Asia); BARDA supported development.","Product anticipated to be available in US by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67843,"accession_number":"0001193125-26-221567","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-05-13T20:02:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.","Total revenue of $0.3M, down from $5.9M in prior-year quarter.","Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.","GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.","R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion."],"consensus_eps_estimate":-0.1836,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107440,"accession_number":"0001193125-26-126244","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.","Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.","Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).","Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.","Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107439,"accession_number":"0001193125-26-032004","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Director resigns; SEC concludes investigation with no enforcement action","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.","Company intends to enter consulting agreement with Mahadevia for continued support.","SEC concluded its investigation on Jan 20, 2026; will not recommend enforcement action against company at this time.","Investigation was previously disclosed in SEC periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123783,"accession_number":"0001193125-25-325821","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GSK files NDA resubmission for tebipenem HBr; Spero to receive $25M milestone in Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["GSK resubmitted NDA to FDA for oral carbapenem tebipenem HBr for cUTI/pyelonephritis.","Resubmission triggers $25 million milestone payment to Spero, expected Q1 2026.","Spero's tebipenem HBr is investigational; approval not guaranteed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123782,"accession_number":"0001193125-25-280518","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.","Cash and equivalents $48.6M as of Sep 30, 2025; company expects funding into 2028.","Phase 3 PIVOT-PO trial of tebipenem HBr met primary endpoint; GSK to submit NDA to FDA in Q4 2025 with decision expected 2H 2026.","SPR720 program for NTM pulmonary disease discontinued in Q3 2025 after Phase 2a/1 data review.","R&D expenses fell to $8.6M from $26.9M due to lower PIVOT-PO and SPR720 costs."],"consensus_eps_estimate":-0.255,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":25505000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140463,"accession_number":"0001193125-25-178970","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.","Phase 3 PIVOT-PO trial of tebipenem HBr in cUTI met primary endpoint; IDMC stopped early for efficacy.","Spero and GSK plan to submit data to FDA in 2H 2025; potential milestone payments adjusted to up to $101M from $150M.","Cash $31.2M at June 30 plus $23.8M GSK milestone received Aug 2025; runway expected into 2028.","Esther Rajavelu appointed CEO/President effective May 2, 2025, continuing as CFO."],"consensus_eps_estimate":-0.3876,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":20063000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158147,"accession_number":"0001193125-25-142807","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Spero Therapeutics stockholders approve 3M share increase to 2017 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan increasing authorized shares by 3,000,000.","Reelected Class II directors Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu to 2028 meeting.","Ratified PricewaterhouseCoopers as independent auditor for fiscal year 2025.","Advisory vote on executive compensation passed with 25.2M for, 0.6M against.","Quorum of 40,015,633 shares (71.57%) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158146,"accession_number":"0001193125-25-128680","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spero/GSK Phase 3 PIVOT-PO trial for tebipenem HBr meets primary endpoint, stops early for efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tebipenem HBr met non-inferiority vs IV imipenem-cilastatin in 1,690 cUTI patients; IDMC recommended early stop.","No new safety concerns; diarrhea and headache most common adverse events.","GSK plans FDA filing in second half 2025; could be first oral carbapenem for cUTIs in US.","cUTIs affect ~2.9M US cases/year with >$6B in healthcare costs; IV-only standard currently.","Supported by BARDA funding and QIDP/Fast Track designations from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158145,"accession_number":"0001193125-25-118882","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.","Cash $48.9M plus $23.75M earned GSK milestone payments provides runway into Q2 2026.","Esther Rajavelu appointed President & CEO effective May 2, 2025; continues as CFO & Treasurer.","Phase 3 PIVOT-PO interim analysis for tebipenem HBr expected Q2 2025; SPR720 program suspended after missing endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":5874000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158144,"accession_number":"0001193125-25-100433","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.","Rajavelu continues as CFO and Treasurer; base salary $620K, target bonus 50%, 185,000 RSUs vesting over 4 years.","Former CEO Sath Shukla mutually separates; receives salary continuation of $615,825, cash bonus $307,913, and retention bonus $452,813.","Company expects update on PIVOT-PO Phase 3 trial for tebipenem HBr this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176512,"accession_number":"0001193125-25-065633","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero posts Q4 net loss of $20.9M; revenue down 80% YoY; pipeline setbacks and SEC Wells Notice","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.9M in Q4 2024 vs net income of $51.2M in Q4 2023; diluted EPS loss of $(0.38).","Total revenue fell to $15.0M from $73.5M YoY, driven by lower collaboration revenue from GSK and Pfizer.","Tebipenem HBr Phase 3 PIVOT-PO interim analysis expected Q2 2025; SPR720 Phase 2a missed primary endpoint with three cases of grade 3 hepatotoxicity; SPR206 discontinued.","Leadership change: Esther Rajavelu appointed Interim President and CEO in January 2025 following a Wells Notice from SEC related to disclosures in 2022.","Cash of $52.9M as of Dec 31, 2024; plus GSK milestones provide runway into Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176511,"accession_number":"0001193125-25-042785","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Spero Therapeutics receives Nasdaq bid price deficiency notice; has until Aug 25, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Spero on Feb 25, 2025 that its stock closed below $1.00 for 30 consecutive trading days.","Compliance deadline is August 25, 2025; cure requires closing at $1.00+ for 10 consecutive business days.","If not cured, Spero may transfer to Nasdaq Capital Market and consider reverse stock split for 180-day extension.","Stock continues trading on Nasdaq GS under SPRO; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176510,"accession_number":"0001193125-25-004063","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","5.02","8.01","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.","CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.","Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.","Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.","Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193365,"accession_number":"0001193125-24-258540","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.","Phase 3 PIVOT-PO trial of tebipenem HBr on track to complete enrollment in 2H 2025 (target ~2,648 patients).","SPR720 program suspended after Phase 2a missed primary endpoint; three cases of reversible grade 3 hepatotoxicity.","Cash and equivalents $76.3M; Oct 2024 restructuring and ~39% RIF extend cash runway into mid-2026.","SPR206 IND cleared for Phase 2 in HABP/VABP, but initiation contingent on non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":32933000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193364,"accession_number":"0001193125-24-246627","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","2.05","7.01","8.01","9.01"],"status":"ready","headline":"Spero suspends SPR720 development after Phase 2a miss; cuts workforce 39%, extends cash runway to mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPR720 Phase 2a interim analysis did not meet primary endpoint; 3 cases of reversible grade 3 hepatotoxicity at 1,000 mg dose.","Company restructuring with ~39% workforce reduction; expects ~$1.1M in cash restructuring charges.","Unaudited Q3 2024 cash ~$76.3M; cash runway extended into mid-2026.","Tebipenem HBr PIVOT-PO Phase 3 trial on track for enrollment completion in 2H 2025.","IND cleared for SPR206 Phase 2 trial in HABP/VABP, contingent on non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209710,"accession_number":"0001193125-24-216310","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Spero Therapeutics updates investor presentation; no material new financial or operational data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated investor presentation dated September 9, 2024, under Regulation FD.","Presentation available on Spero's IR website; company disclaims obligation to update after that date.","No specific financial metrics, pipeline updates, or guidance changes were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209709,"accession_number":"0001193125-24-193913","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.","Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.","SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.","CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.","Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":19464000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227852,"accession_number":"0001193125-24-153034","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Spero Therapeutics shareholders approve 3M share increase for 2017 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Stock Incentive Plan, adding 3,000,000 authorized shares.","All three Class I director nominees (Scott Jackson, John C. Pottage Jr., Cynthia Smith) were reelected.","Ratification of PricewaterhouseCoopers as auditor for FY2024 passed with 36.6M votes for.","Advisory vote on executive compensation approved (23.9M for, 442k against).","Quorum of 68.23% of outstanding shares present at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227851,"accession_number":"0001193125-24-139364","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.","Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.","SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.","SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.","Reaffirmed cash runway into late 2025 based on current operating plans."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":9267000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246646,"accession_number":"0001193125-24-082060","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Spero Therapeutics sets 2024 Annual Meeting for May 29, 2024 (online)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting on May 29, 2024, will be held entirely online via virtual format.","Meeting scheduled more than 30 days before prior year's meeting (Oct 5, 2023), triggering special notice under Bylaws.","Stockholders should review Bylaws for deadlines on Rule 14a-8 proposals and director nominations.","Proxy statement will detail online attendance, voting, and question submission procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246645,"accession_number":"0001193125-24-066825","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).","Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.","Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.","SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.","Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246644,"accession_number":"0001193125-24-029913","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spero Therapeutics Chief Legal Officer Tamara Joseph to depart March 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tamara Joseph, Chief Legal Officer and Corporate Secretary, is leaving effective March 6, 2024 to pursue other interests.","Severance includes continuation of base salary for nine months totaling $356,298.75, plus prorated cash bonus of $34,266.98.","Joseph will provide consulting services on an hourly as-needed basis for nine months at $395/hour; stock options and RSUs continue vesting.","Separation and Consulting Agreement entered February 9, 2024; full terms to be filed with Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246643,"accession_number":"0001193125-24-003807","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Spero Therapeutics files updated investor presentation; no specific new material details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated its corporate investor presentation on January 8, 2024.","Presentation made available on company's website; content not summarized in the 8-K.","No financial or operational updates disclosed in the filing body.","Company disclaims obligation to update the presentation after this date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246642,"accession_number":"0001193125-24-002894","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Spero Therapeutics provides 2024 outlook; cash $76.3M, runway into late 2025; SPR720 Phase 2a data due 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents of $76.3M as of Dec 31, 2023 (unaudited).","Cash plus $95M in GSK development milestones expected to fund operations into late 2025.","PIVOT-PO Phase 3 trial of tebipenem HBr for cUTI initiated; target enrollment ~2,648 patients; completion expected 2H 2025.","SPR720 Phase 2a topline data for NTM-PD expected in second half of 2024.","Company entitled to $95M in development milestones from GSK, payable in four equal installments over two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246641,"accession_number":"0001193125-24-000249","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spero starts Phase 3 PIVOT-PO trial of tebipenem HBr; $95M milestone payable over two years from GSK","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient first visit for Phase 3 PIVOT-PO trial (cUTI/AP) targeting ~2,648 patients.","Primary endpoint: overall response (composite of clinical cure + microbiological eradication) at test-of-cure.","Non-inferiority vs IV imipenem cilastatin with 10% NI margin in microbiological ITT population.","GSK license: $95M development milestone payable in 4 equal semiannual installments over 2 years.","Additional milestones: $25M on FDA submission, up to $150M commercial, up to $225M sales, plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264068,"accession_number":"0001193125-23-276030","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q3 net loss $3.2M, revenue $25.5M on $30M GSK milestone; FDA SPA for Phase 3 tebipenem HBr","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($0.06/shr) vs $11.7M loss ($0.33/shr) YoY; revenue $25.5M vs $2.0M YoY driven by $23.2M GSK collaboration revenue.","Cash $93.8M expected to fund operations into H2 2025; received $30M development milestone from GSK under tebipenem HBr license.","FDA granted Special Protocol Assessment for Phase 3 PIVOT-PO trial of oral tebipenem HBr in cUTI/AP; enrollment start expected Q4 2023.","Phase 2a SPR720 trial for NTM-PD ongoing; topline data expected H2 2024. IND for SPR206 planned Q4 2023.","Sath Shukla appointed President and CEO (Aug 1); Esther Rajavelu named CFO and CBO (Nov 1), replacing prior CFO role."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":30259000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264067,"accession_number":"0001193125-23-267758","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Spero Therapeutics appoints Esther Rajavelu as CFO and CBO effective Nov 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Esther Rajavelu appointed CFO and Chief Business Officer; assumes principal financial officer role after Q3 10-Q filing.","Annual base salary of $475,000; sign-on bonus of $50,000; target annual cash bonus of 40% of base salary.","Grant of 300,000 RSUs under inducement plan, vesting in equal annual installments over four years starting Nov 6, 2024.","Interim CFO Stephen DiPalma continues until Q3 10-Q filed; may consult post-transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264065,"accession_number":"0001193125-23-256865","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K/A","filed_at":"2023-10-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Spero Therapeutics corrects 8-K: charter amendment was not approved; files Certificate of Correction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to 8-K discloses tabulation error in October 5 annual meeting vote.","Charter amendment proposals (officer exculpation, federal forum clause) did not receive required votes.","Certificate of Correction filed Oct 16, 2023 to undo previously recorded charter amendment.","Company states charter remains unchanged as a result of the correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264066,"accession_number":"0001193125-23-253136","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Spero Therapeutics stockholders approve 2.5M share increase to 2017 Plan and charter amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,500,000.","Charter amendment adding officer exculpation and federal forum selection clause approved and filed with Delaware on Oct 6.","All three Class III director nominees re-elected: Deshpande, Mahadevia, Tregoning with support from majority of votes cast.","Advisory vote on executive compensation approved; frequency set to annual."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281303,"accession_number":"0001193125-23-209064","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero reports Q2 loss $11.9M; FDA SPA for tebipenem HBr P3 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M ($0.23/sh) vs $28.7M ($0.87) in Q2 2022; revenue $2.7M.","FDA SPA agreement on design of Phase 3 PIVOT-PO trial for tebipenem HBr; first patient expected Q4 2023.","Sath Shukla appointed President and CEO effective Aug 1; succeeds Ankit Mahadevia (now Chairman).","Cash $77.7M + $30M GSK milestone; cash runway into H2 2025.","SPR720 Phase 2 trial enrolling, topline data H2 2024; SPR206 IND planned Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":4786000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281302,"accession_number":"0001193125-23-198589","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA agrees to SPA for Spero's Phase 3 tebipenem HBr trial; $30M milestone due from GSK","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Special Protocol Assessment (SPA) for pivotal Phase 3 PIVOT-PO trial of oral tebipenem HBr vs IV imipenem in cUTI/acute pyelonephritis.","Positive results from PIVOT-PO plus prior studies could support FDA approval for a limited use indication.","Spero to receive $30M development milestone from GSK upon invoicing; additional milestones up to $495M plus tiered royalties.","PIVOT-PO first patient first visit expected in Q4 2023; trial uses 10% non-inferiority margin per FDA guidance.","SPR720 Phase 2 enrollment continues; top-line data now expected in H2 2024 (slower than prior guidance)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300082,"accession_number":"0001193125-23-166543","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Spero Therapeutics appoints Sath Shukla as CEO, Mahadevia becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Ankit Mahadevia steps down effective Aug 1, 2023; becomes Chairman of the Board.","CFO Satyavrat 'Sath' Shukla appointed CEO and President, also joins Board.","Stephen DiPalma appointed Interim CFO, effective Aug 1, 2023.","Chairman Milind Deshpande steps down but remains director; Patrick Vink named Lead Independent Director.","Mahadevia to receive $54k/month consulting fee through Jan 2024, then $310/hour through July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300081,"accession_number":"0001193125-23-142023","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics reports Q1 2023 net loss of $13.3M; provides pipeline updates for SPR720, tebipenem HBr, and SPR206","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.3M ($0.25 per share) in Q1 2023, compared to net loss of $32.8M ($1.01 per share) in Q1 2022.","Cash and cash equivalents of $96.3M as of March 31, 2023; company expects sufficient funding beyond 2024.","SPR720 Phase 2 trial in NTM-PD on track for top line data readout in first half of 2024.","Tebipenem HBr: SPA agreement update expected mid-2023; Phase 3 cUTI trial initiation expected in 2H 2023.","SPR206: IND submission for Phase 2 trial in hospital-acquired/ventilator-associated bacterial pneumonia expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2069000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320160,"accession_number":"0001193125-23-085566","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics reports Q4 net income of $26.8M; GSK deal provides $66M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net income $26.8M ($0.55 EPS) vs net loss $29.2M in Q4 2021; full-year net loss $46.4M ($1.23 loss per share).","Total revenue Q4 2022 $47.4M (up from $2.7M) driven by $46.1M collaboration revenue from GSK and Pfizer deals.","Cash and equivalents $109.1M as of Dec 31, 2022; company expects runway beyond 2024.","Initiated Phase 2 trial of SPR720 in NTM-PD; top-line data expected in first half of 2024.","GSK license for tebipenem HBr: $66M upfront, $9M equity investment, up to $525M milestones plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320159,"accession_number":"0001193125-23-021612","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spero Therapeutics names Timothy Keutzer Chief Operating Officer effective Feb 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Keutzer, previously Chief Development Officer, appointed COO effective February 1, 2023.","Base salary set at $459,000; annual cash bonus target of up to 40% of base salary.","Grant of 4-year vesting RSUs worth $500,000 on effective date.","Severance: 9 months salary without Cause/Good Reason; on change of control, 12 months salary plus equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320158,"accession_number":"0001193125-23-004190","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Spero reports preliminary cash of ~$109M as of Dec 31, 2022; updates investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$109M as of Dec 31, 2022 (unaudited, subject to change).","Updated investor presentation highlights SPR720 as a potential first-line oral therapy for NTM infections.","Partnerships for tebipenem HBr and SPR206 are noted to support a strong balance sheet.","Audited FY2022 financials are not yet available; preliminary estimate may differ materially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338302,"accession_number":"0001193125-22-284579","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Therapeutics Q3 net loss narrows to $11.7M; secures $75M from GSK license and equity investment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.7M ($0.33/shr) vs $22.5M ($0.70/shr) in Q3 2021; revenue $2M down from $3.1M.","Cash $50.4M at Sep 30; post-Q3 received $9M GSK equity, $66M upfront invoiced; runway extended beyond 2024.","GSK license for tebipenem HBr closed; $66M upfront, $9M equity, up to $525M milestones plus tiered royalties.","SPR720 Phase 2 trial initiated for NTM pulmonary disease; top line data expected 1H 2024.","Kamal Hamed joined as CMO in Sep 2022; received inducement awards of 210k RSUs and 140k PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":6068000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338301,"accession_number":"0001193125-22-279724","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Spero Therapeutics closes exclusive license agreement with GSK for tebipenem HBr","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $66 million upfront payment from GSK under the exclusive license agreement.","GSK affiliate purchased 7,450,000 shares of Spero common stock for approximately $9 million.","Spero eligible for up to $525 million in development, sales, and commercial milestones plus tiered royalties.","Spero will conduct a follow-up Phase 3 trial; GSK responsible for further development and commercialization outside Meiji Seika territories.","GSK granted exclusive license to develop and commercialize tebipenem HBr in all territories except Japan and certain Asian countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355669,"accession_number":"0001193125-22-248772","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Spero licenses tebipenem HBr to GSK for $66M upfront, up to $525M milestones plus tiered royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GSK gets exclusive license to develop and commercialize oral carbapenem antibiotic tebipenem HBr outside Japan and certain Asian countries.","Spero receives $66M upfront; potential milestones: $150M Phase III delivery, $150M first sale (US/EU), $225M sales milestones up to $1B+.","Tiered royalties low-single to low-double digit increase if net sales exceed $1B.","GSK invests $9M in Spero common stock at ~$1.20805/share (7.45M shares), with lock-up and standstill provisions.","Spero to start a new Phase 3 trial in 2023; closing expected Q4 2022 subject to HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355668,"accession_number":"0001193125-22-247168","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Spero Therapeutics stockholders approve 2M share increase to 2017 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,000,000 (total 4,608,374 for new awards).","Vote: 11,537,809 for, 8,787,318 against, 3,114,531 abstentions, 4,552,916 broker non-votes.","Directors Patrick Vink and Frank Thomas re-elected at annual meeting on September 15, 2022.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355667,"accession_number":"0001193125-22-238439","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Spero Therapeutics: FDA agrees single additional Phase 3 trial could support approval of tebipenem HBr for cUTI","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA indicated positive results from one additional Phase 3 trial, plus confirmatory nonclinical evidence, could support approval.","Spero plans to advance tebipenem HBr development and potential commercialization through external partnership.","Type A meeting follows June 2022 CRL; FDA aligned on key components for pivotal trial design, with possible SPA.","If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355666,"accession_number":"0001193125-22-217351","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spero Q2 net loss widens to $28.7M; tebipenem HBr NDA receives CRL; Phase 2 SPR720 trial set for Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.7M ($0.87/share) vs $18.6M ($0.63/share) in Q2 2021; revenue $2.0M down from $5.1M.","FDA issued Complete Response Letter for tebipenem HBr NDA; Type A meeting completed to discuss path forward.","Phase 2 trial of SPR720 in NTM-PD expected to start Q4 2022; interim data mid-2023.","SPR206 regulatory milestone achieved under Pfizer license; $5M payment expected in Q3 2022.","Cash, equivalents and marketable securities $45.4M; believes funding into late 2023 via restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":4062000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355665,"accession_number":"0001193125-22-187190","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spero Therapeutics grants CEO $254K cash + $508K RSU, CFO $168K cash + $336K RSU retention awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Ankit Mahadevia receives $254K cash bonus (Nov 30, 2022) and up to $508K in stock based on performance criteria.","CFO Satyavrat Shukla receives $168K cash bonus (Nov 30, 2022) and up to $336K in stock based on performance criteria.","Awards tied to continued employment through May 31, 2023 and achievement of pipeline, BD, and financial stewardship goals.","Unvested RSUs lapse if performance criteria not met by May 31, 2023; vesting acceleration only in certain change-in-control events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373916,"accession_number":"0001193125-22-182828","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA rejects Spero's tebipenem HBr NDA for cUTI; additional clinical study required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Complete Response Letter on June 27, 2022 for tebipenem HBr oral tablets cUTI NDA.","FDA determined Phase 3 ADAPT-PO study insufficient; additional clinical study needed.","Company plans to request a Type A meeting with FDA to discuss path forward.","CEO expressed disappointment but commitment to pursue regulatory approval and potential partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373915,"accession_number":"0001193125-22-169252","cik":1701108,"company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Spero pays $54.5M to terminate HCR revenue interest agreement, regains Tebi asset rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash payment of $54.5M (exact $54,484,895) on June 7, 2022 to terminate HCR financing agreement and release all liens.","All rights to tebipenem (Tebi) assets revert to Spero; company previously ceased Tebi commercialization on May 3, 2022.","Contingent additional payment of up to $10M+ if a change of control occurs by Dec 31, 2022, based on equity value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171677931.3088737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-07T23:59:59+00:00|373915"}